Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Cases from Down South
Description
Lauren Graham from the University of Alabama presented challenging dermatological cases during a seminar. One case involved a 46-year-old woman diagnosed with amyopathic dermatomyositis who had an initial positive ANA and presented various skin lesions. After unsuccessful treatments with hydroxychloroquine and methotrexate, she participated in a clinical trial with an anti-interferon drug, leading to significant skin improvement. However, she relapsed post-trial and required switching to multiple treatments, including IVIG and an investigational antibody. Another case detailed a 22-year-old woman with a history of failing various treatments for her dermatomyositis, emphasizing the importance of methotrexate, even in patients fearful of its side effects. Graham addressed the need to manage patients' quality of life, particularly addressing severe itching that leads to skin thickening and worsening conditions. A case of recalcitrant subacute cutaneous lupus highlighted the necessity of smoking cessation and careful management of treatments. Further, caution was advised regarding treatment-induced adverse reactions. Each case reinforced the significance of employing old treatments, understanding when to act decisively, and considering systemic issues that may complicate dermatological conditions. Overall, Graham's discussion stressed the integration of clinical knowledge and patient-centered care to address complex dermatological cases effectively.
View moreConclusions
- Cases of amyopathic dermatomyositis can be challenging, and thorough clinical evaluation is essential for proper diagnosis and treatment.
- Hydroxychloroquine may cause adverse skin reactions in patients with dermatomyositis, and additional caution is needed in patients with specific antibody profiles.
- Methotrexate and mycophenolate mofetil can be effective treatments for dermatomyositis, but careful monitoring for adverse events is necessary.
- New therapies such as anti-interferon monoclonal antibodies show promise for treatment-resistant dermatomyositis, highlighting the need for ongoing clinical trials.
- Calcinosis and itching are significant issues in dermatomyositis that require careful management to improve patient quality of life.
- Interventions for dermatomyositis should be adapted based on individual patient needs, considering previous treatment failures and overall health status.
- Old treatments like thalidomide may still have a role in managing recalcitrant cases of subacute cutaneous lupus despite potential side effects.
- Bloom, et al. J Rheum. 1994;21.
- Gonzalez, JAAD. 2019;81(3).
- Pelle MT, Callen JP. Arch Dermatol. 2002;138(9):1231.
- Rypka, et al. Derm Onlin J. 2023; 29(5).
- Wolstencroft, et al. JAMA Derm. 2018 Oct 1;154(10):1199.
- Shah, JAMA Derm, 2024.
- Grinnell, et al. Br J Dermatol, 2022.
- Gerami, JAAD, 2006.
- Aitmehdi, et al. JAAD, 2021.